Beta-casein A2 composition for bowel inflammation prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases and irritable bowel syndrome often rely on pharmaceuticals and dietary modifications, which may not be effective in addressing the inflammation caused by beta-casein A1 consumption, leading to ongoing bowel inflammation.
Innovation Solution
A composition containing at least 50% beta-casein A2 is used to prevent or reduce the risk of bowel inflammation by eliminating or minimizing the intake of beta-casein A1, which is linked to inflammatory responses, through the use of milk and milk-derived products with predominantly beta-casein A2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If beta-casein A1 is consumed in the diet, then protein nutrition is provided, but bowel inflammation is induced through BCM-7 production
Solution Approach 1:
The invention extracts and eliminates the harmful beta-casein A1 component from the diet while retaining beneficial protein sources. By specifically avoiding beta-casein A1-containing milk products and substituting with beta-casein A2-containing products, the harmful factor (BCM-7 production) is removed while maintaining adequate protein nutrition from alternative sources.
Solution Approach 2:
The invention changes the protein source parameter from beta-casein A1 to beta-casein A2. This parameter change alters the enzymatic digestion pathway, preventing BCM-7 formation while maintaining protein nutrition. The single amino acid difference (histidine vs proline at position 67) fundamentally changes the digestion outcome.
2Reliability
If conventional treatments are used for bowel inflammation, then symptom management is attempted, but underlying inflammation caused by beta-casein A1 consumption persists
Solution Approach 1:
The invention applies preliminary action by eliminating the root cause (beta-casein A1 consumption) before inflammation can develop or persist. By proactively changing the diet to exclude beta-casein A1, the prevention occurs upstream, avoiding the need for reactive treatment of ongoing inflammation and its associated symptoms.
3Object-affected harmful factors
If beta-casein A2 is used as the primary protein source, then bowel inflammation is prevented, but dietary options are limited
Solution Approach 1:
The invention applies universality by identifying beta-casein A2 as a universal safe protein source that can replace beta-casein A1 across multiple food products and dietary contexts. Beta-casein A2-containing milk products serve multiple functions: providing protein nutrition, maintaining satiety, and preventing bowel inflammation, making them a versatile substitute in various dietary applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of beta-casein A2-rich compositions effectively reduces bowel inflammation by minimizing the production of BCM-7, a peptide associated with opioid receptors, thereby alleviating symptoms and improving bowel health without systemic inflammation.
Implementation Method 1
The presence of histidine at position 67 allows a protein fragment comprising seven amino acids, known as beta-casomorphin-7 (BCM-7), to be produced on enzymatic digestion. In the case of beta-casein A2, position 67 is occupied by a proline which hinders cleavage of the amino acid bond at that location, Thus, BCM-7 is not a digestion product of beta-casein A2.
Data Source
AI summary
The use of a composition for preventing or reducing the risk of inflammation of the bowel in an animal, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 50% by weight beta-casein A2.